- Home
- BKH vs ABVX Comparison
BKH vs ABVX Comparison
Compare BKH & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKH
- ABVX
- Stock Information
- Founded
- BKH 1941
- ABVX 2013
- Country
- BKH United States
- ABVX France
- Employees
- BKH N/A
- ABVX N/A
- Industry
- BKH Electric Utilities: Central
- ABVX
- Sector
- BKH Utilities
- ABVX
- Exchange
- BKH Nasdaq
- ABVX Nasdaq
- Market Cap
- BKH 4.4B
- ABVX 5.3B
- IPO Year
- BKH N/A
- ABVX N/A
- Fundamental
- Price
- BKH $59.69
- ABVX $88.03
- Analyst Decision
- BKH Hold
- ABVX Buy
- Analyst Count
- BKH 3
- ABVX 7
- Target Price
- BKH $66.00
- ABVX $74.86
- AVG Volume (30 Days)
- BKH 708.7K
- ABVX 1.1M
- Earning Date
- BKH 07-30-2025
- ABVX 08-11-2025
- Dividend Yield
- BKH 4.54%
- ABVX N/A
- EPS Growth
- BKH N/A
- ABVX N/A
- EPS
- BKH 3.97
- ABVX N/A
- Revenue
- BKH $2,242,900,000.00
- ABVX $11,444,012.00
- Revenue This Year
- BKH $6.50
- ABVX $25.23
- Revenue Next Year
- BKH $2.87
- ABVX N/A
- P/E Ratio
- BKH $15.01
- ABVX N/A
- Revenue Growth
- BKH 5.40
- ABVX 128.98
- 52 Week Low
- BKH $54.92
- ABVX $4.77
- 52 Week High
- BKH $65.59
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- BKH 51.01
- ABVX 86.74
- Support Level
- BKH $59.03
- ABVX $78.00
- Resistance Level
- BKH $60.02
- ABVX $78.49
- Average True Range (ATR)
- BKH 0.93
- ABVX 3.31
- MACD
- BKH -0.22
- ABVX -0.56
- Stochastic Oscillator
- BKH 21.22
- ABVX 81.06
About BKH Black Hills Corporation
Black Hills Corp is a U.S.-based energy company that operates through its Electric Utilities and Gas Utilities segment. These segments operate in states in the Midwest and mountain regions in the U.S. The company's customers include residential, commercial, industrial, and municipal consumers. These customers are residential. Black Hills derives the majority of its revenue from its utility business group, specifically from gas utilities.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.